Skip to main content
  • FDA Approves Rivaroxaban for CV Prevention in CAD, PAD

    Low dose to arrive in the U.S. next week

    Rivaroxaban (Xarelto) was approved for another indication, this time the long-term prevention of major adverse cardiovascular events in people with coronary artery disease (CAD) and peripheral artery disease (PAD), Janssen announced in a press release.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details